Novavax, Inc. (NASDAQ: NVAX) is off to an incredibly strong start to the trading session this morning, and for good reason. The company published data from a clinical trial that proved to be overwhelmingly positive. Of course, this led to excitement among investors, sending the stock toward the top. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:36), NVAX is trading at $1.12 per share after a gain of $0.10 per share or 9.79% thus faro today.
NVAX Posts Positive Clinical Data
As mentioned above, Novavax is off to an incredibly strong start to the trading session after the company released data from the second of two Phase 2 clinical trials. The data surrounds the company’s RSV F Vaccine in women of child bearing age with the intention of protecting infants from the RSV disease.
In the data release, NVAX showed a significant antibody response elicited by the vaccine. This response included a 11.6 to 12.7 – fold increase in anti-F IgG response in women receiving a single dose of 120 µg RSV F Vaccine with 0.2 or 0.4 mg of aluminum. The antibody responses that were seen peaked at the 14 day mark and persisted at significantly elevated levels for the full evaluation period of 3 months. In a statement, Gregory Glenn, M.D., President of Research and Development at NVAX, had the following to offer…
“The Western Blot finding from this trial, which demonstrates a reduction in recent RSV infections of approximately 52% in the vaccine relative to the placebo arms, is consistent with the Western Blot data we reported from a comparable trial and population in September of 2015. Together, these data suggest that the RSV F Vaccine provided protection against RSV infection in controlled trials of over 1,000 women… The results from this trial not only demonstrate significant increases in anti-F IgG, PCA and microneutralizing antibody titers in response to a 120 µg dose of the RSV F Vaccine with 0.4 mg aluminum, the same dose and regimen used in our global Phase 3 trial, Prepare, they are consistent with the immunogenicity results reported in our prior trial in women of child bearing age. While it was not the primary endpoint in the trial, the Western Blot data suggest the potential to protect both the pregnant mothers and their infants from RSV disease.”
Stop wasting your time! Find winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on NVAX. In particular, we’re interested in following the company with regard to the ongoing work on the RSV F vaccine as the data seems to support the idea that this vaccine will be an influential vaccine in avoidance of the RSV infection. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks.
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!